FDA approves Prolensa for pain inflammation after cataract surgery

The U.S. Food and Drug Administration approved Bausch + Lomb’s new drug application for bromfenac ophthalmic solution, according to a company news release.Prolensa (bromfenac ophthalmic solution 0.07%), a once-daily topical NSAID, is designed for the treatment of ocular inflammation and reduction of ocular pain after cataract surgery.

Full Story →